APO Research
Talk to an analyst

APO RESEARCH · REPORT

Primary Biliary Cirrhosis Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Primary Biliary Cirrhosis Drug Market Outlook and Growth Opportunities 2026

19 December 2025197 pages

Choose your research edition.

Industry ResearchPrimary Biliary Cirrhosis Drug Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Primary Biliary Cirrhosis Drug Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Primary Biliary Cirrhosis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Primary Biliary Cirrhosis Drug Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Primary Biliary Cirrhosis Drug Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Primary Biliary Cirrhosis Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Primary Biliary Cirrhosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Primary Biliary Cirrhosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Primary Biliary Cirrhosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Primary Biliary Cirrhosis Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Primary Biliary Cirrhosis Drug market include AlbireoPharma, CymaBay Therapeutics, Inc., Dr. Falk Pharma GmbH, Enanta Pharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., MediGene AG, NGM Biopharmaceuticals, Inc., Virobay Inc. and GlaxoSmithKline Plc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Primary Biliary Cirrhosis Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Primary Biliary Cirrhosis Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Primary Biliary Cirrhosis Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Primary Biliary Cirrhosis Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Primary Biliary Cirrhosis Drug Segment by Company

AlbireoPharma

CymaBay Therapeutics, Inc.

Dr. Falk Pharma GmbH

Enanta Pharmaceuticals, Inc.

Intercept Pharmaceuticals, Inc.

MediGene AG

NGM Biopharmaceuticals, Inc.

Virobay Inc.

GlaxoSmithKline Plc

Johnson & Johnson

Primary Biliary Cirrhosis Drug Segment by Type

Budesonide

NGM-282

MBX-8025

GSK-2330672

FFP-104

Others

Primary Biliary Cirrhosis Drug Segment by Application

Clinic

Hospital

Others

Primary Biliary Cirrhosis Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Primary Biliary Cirrhosis Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Primary Biliary Cirrhosis Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Primary Biliary Cirrhosis Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Primary Biliary Cirrhosis Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Primary Biliary Cirrhosis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Primary Biliary Cirrhosis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Primary Biliary Cirrhosis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Primary Biliary Cirrhosis Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Primary Biliary Cirrhosis Drug industry.

Chapter 3: Detailed analysis of Primary Biliary Cirrhosis Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Primary Biliary Cirrhosis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Primary Biliary Cirrhosis Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Primary Biliary Cirrhosis Drug Industry Trends Table 2. Primary Biliary Cirrhosis Drug Industry Drivers Table 3. Primary Biliary Cirrhosis Drug Industry Opportunities and Challenges Table 4. Primary Biliary Cirrhosis Drug Industry Restraints Table 5. Global Primary Biliary Cirrhosis Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Primary Biliary Cirrhosis Drug Revenue Share by Company (2021-2026) Table 7. Global Primary Biliary Cirrhosis Drug Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Primary Biliary Cirrhosis Drug Sales Volume Share by Company (2021-2026) Table 9. Global Primary Biliary Cirrhosis Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Primary Biliary Cirrhosis Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Primary Biliary Cirrhosis Drug Key Company Manufacturing Base & Headquarters Table 12. Global Primary Biliary Cirrhosis Drug Company, Product Type & Application Table 13. Global Primary Biliary Cirrhosis Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Primary Biliary Cirrhosis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Budesonide Table 18. Significant Companies of NGM-282 Table 19. Significant Companies of MBX-8025 Table 20. Significant Companies of GSK-2330672 Table 21. Significant Companies of FFP-104 Table 22. Significant Companies of Others Table 23. Global Primary Biliary Cirrhosis Drug Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 24. Global Primary Biliary Cirrhosis Drug Sales Volume by Type (2021-2026) & (W Units) Table 25. Global Primary Biliary Cirrhosis Drug Sales Volume by Type (2027-2032) & (W Units) Table 26. Global Primary Biliary Cirrhosis Drug Sales Volume Share by Type (2021-2026) Table 27. Global Primary Biliary Cirrhosis Drug Sales Volume Share by Type (2027-2032) Table 28. Global Primary Biliary Cirrhosis Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Primary Biliary Cirrhosis Drug Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Primary Biliary Cirrhosis Drug Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Primary Biliary Cirrhosis Drug Sales Value Share by Type (2021-2026) Table 32. Global Primary Biliary Cirrhosis Drug Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Clinic Table 34. Significant Companies of Hospital Table 35. Significant Companies of Others Table 36. Global Primary Biliary Cirrhosis Drug Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 37. Global Primary Biliary Cirrhosis Drug Sales Volume by Application (2021-2026) & (W Units) Table 38. Global Primary Biliary Cirrhosis Drug Sales Volume by Application (2027-2032) & (W Units) Table 39. Global Primary Biliary Cirrhosis Drug Sales Volume Share by Application (2021-2026) Table 40. Global Primary Biliary Cirrhosis Drug Sales Volume Share by Application (2027-2032) Table 41. Global Primary Biliary Cirrhosis Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Primary Biliary Cirrhosis Drug Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Primary Biliary Cirrhosis Drug Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Primary Biliary Cirrhosis Drug Sales Value Share by Application (2021-2026) Table 45. Global Primary Biliary Cirrhosis Drug Sales Value Share by Application (2027-2032) Table 46. Global Primary Biliary Cirrhosis Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 47. Global Primary Biliary Cirrhosis Drug Sales by Region (2021-2026) & (W Units) Table 48. Global Primary Biliary Cirrhosis Drug Sales Market Share by Region (2021-2026) Table 49. Global Primary Biliary Cirrhosis Drug Sales by Region (2027-2032) & (W Units) Table 50. Global Primary Biliary Cirrhosis Drug Sales Market Share by Region (2027-2032) Table 51. Global Primary Biliary Cirrhosis Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Primary Biliary Cirrhosis Drug Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Primary Biliary Cirrhosis Drug Sales Value Share by Region (2021-2026) Table 54. Global Primary Biliary Cirrhosis Drug Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Primary Biliary Cirrhosis Drug Sales Value Share by Region (2027-2032) Table 56. Global Primary Biliary Cirrhosis Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 57. Global Primary Biliary Cirrhosis Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 58. Global Primary Biliary Cirrhosis Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 59. Global Primary Biliary Cirrhosis Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Primary Biliary Cirrhosis Drug Sales by Country (2021-2026) & (W Units) Table 61. Global Primary Biliary Cirrhosis Drug Sales Market Share by Country (2021-2026) Table 62. Global Primary Biliary Cirrhosis Drug Sales by Country (2027-2032) & (W Units) Table 63. Global Primary Biliary Cirrhosis Drug Sales Market Share by Country (2027-2032) Table 64. Global Primary Biliary Cirrhosis Drug Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Primary Biliary Cirrhosis Drug Sales Value Market Share by Country (2021-2026) Table 66. Global Primary Biliary Cirrhosis Drug Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Primary Biliary Cirrhosis Drug Sales Value Market Share by Country (2027-2032) Table 68. AlbireoPharma Company Information Table 69. AlbireoPharma Business Overview Table 70. AlbireoPharma Primary Biliary Cirrhosis Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. AlbireoPharma Primary Biliary Cirrhosis Drug Product Portfolio Table 72. AlbireoPharma Recent Development Table 73. CymaBay Therapeutics, Inc. Company Information Table 74. CymaBay Therapeutics, Inc. Business Overview Table 75. CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Product Portfolio Table 77. CymaBay Therapeutics, Inc. Recent Development Table 78. Dr. Falk Pharma GmbH Company Information Table 79. Dr. Falk Pharma GmbH Business Overview Table 80. Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Product Portfolio Table 82. Dr. Falk Pharma GmbH Recent Development Table 83. Enanta Pharmaceuticals, Inc. Company Information Table 84. Enanta Pharmaceuticals, Inc. Business Overview Table 85. Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Portfolio Table 87. Enanta Pharmaceuticals, Inc. Recent Development Table 88. Intercept Pharmaceuticals, Inc. Company Information Table 89. Intercept Pharmaceuticals, Inc. Business Overview Table 90. Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Portfolio Table 92. Intercept Pharmaceuticals, Inc. Recent Development Table 93. MediGene AG Company Information Table 94. MediGene AG Business Overview Table 95. MediGene AG Primary Biliary Cirrhosis Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. MediGene AG Primary Biliary Cirrhosis Drug Product Portfolio Table 97. MediGene AG Recent Development Table 98. NGM Biopharmaceuticals, Inc. Company Information Table 99. NGM Biopharmaceuticals, Inc. Business Overview Table 100. NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Portfolio Table 102. NGM Biopharmaceuticals, Inc. Recent Development Table 103. Virobay Inc. Company Information Table 104. Virobay Inc. Business Overview Table 105. Virobay Inc. Primary Biliary Cirrhosis Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Virobay Inc. Primary Biliary Cirrhosis Drug Product Portfolio Table 107. Virobay Inc. Recent Development Table 108. GlaxoSmithKline Plc Company Information Table 109. GlaxoSmithKline Plc Business Overview Table 110. GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Product Portfolio Table 112. GlaxoSmithKline Plc Recent Development Table 113. Johnson & Johnson Company Information Table 114. Johnson & Johnson Business Overview Table 115. Johnson & Johnson Primary Biliary Cirrhosis Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Johnson & Johnson Primary Biliary Cirrhosis Drug Product Portfolio Table 117. Johnson & Johnson Recent Development Table 118. Key Raw Materials Table 119. Raw Materials Key Suppliers Table 120. Primary Biliary Cirrhosis Drug Distributors List Table 121. Primary Biliary Cirrhosis Drug Customers List Table 122. Research Programs/Design for This Report Table 123. Authors List of This Report Table 124. Secondary Sources Table 125. Primary Sources List of Figures Figure 1. Primary Biliary Cirrhosis Drug Product Image Figure 2. Global Primary Biliary Cirrhosis Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Primary Biliary Cirrhosis Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Primary Biliary Cirrhosis Drug Sales (2021-2032) & (W Units) Figure 5. Global Primary Biliary Cirrhosis Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Primary Biliary Cirrhosis Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Budesonide Image Figure 10. NGM-282 Image Figure 11. MBX-8025 Image Figure 12. GSK-2330672 Image Figure 13. FFP-104 Image Figure 14. Others Image Figure 15. Global Primary Biliary Cirrhosis Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 16. Global Primary Biliary Cirrhosis Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Primary Biliary Cirrhosis Drug Sales Volume Share by Type (2021-2032) Figure 18. Global Primary Biliary Cirrhosis Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Primary Biliary Cirrhosis Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Primary Biliary Cirrhosis Drug Sales Value Share by Type (2021-2032) Figure 21. Clinic Image Figure 22. Hospital Image Figure 23. Others Image Figure 24. Global Primary Biliary Cirrhosis Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 25. Global Primary Biliary Cirrhosis Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Primary Biliary Cirrhosis Drug Sales Volume Share by Application (2021-2032) Figure 27. Global Primary Biliary Cirrhosis Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Primary Biliary Cirrhosis Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Primary Biliary Cirrhosis Drug Sales Value Share by Application (2021-2032) Figure 30. Global Primary Biliary Cirrhosis Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 31. Global Primary Biliary Cirrhosis Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Primary Biliary Cirrhosis Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Primary Biliary Cirrhosis Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Primary Biliary Cirrhosis Drug Sales Value (2021-2032) & (US$ Million) Figure 35. North America Primary Biliary Cirrhosis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Primary Biliary Cirrhosis Drug Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Primary Biliary Cirrhosis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Primary Biliary Cirrhosis Drug Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Primary Biliary Cirrhosis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Primary Biliary Cirrhosis Drug Sales Value (2021-2032) & (US$ Million) Figure 41. South America Primary Biliary Cirrhosis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Primary Biliary Cirrhosis Drug Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Primary Biliary Cirrhosis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Primary Biliary Cirrhosis Drug Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Primary Biliary Cirrhosis Drug Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • Budesonide
  • NGM-282
  • MBX-8025
  • GSK-2330672
  • FFP-104
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • AlbireoPharma
  • CymaBay Therapeutics, Inc.
  • Dr. Falk Pharma GmbH
  • Enanta Pharmaceuticals, Inc.
  • Intercept Pharmaceuticals, Inc.
  • MediGene AG
  • NGM Biopharmaceuticals, Inc.
  • Virobay Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Primary Biliary Cirrhosis Drug Sales Value (2021-2032)
  4. 1.2.2 Global Primary Biliary Cirrhosis Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Primary Biliary Cirrhosis Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Primary Biliary Cirrhosis Drug Market Dynamics
  1. 2.1 Primary Biliary Cirrhosis Drug Industry Trends
  2. 2.2 Primary Biliary Cirrhosis Drug Industry Drivers
  3. 2.3 Primary Biliary Cirrhosis Drug Industry Opportunities and Challenges
  4. 2.4 Primary Biliary Cirrhosis Drug Industry Restraints
3 Primary Biliary Cirrhosis Drug Market by Company
  1. 3.1 Global Primary Biliary Cirrhosis Drug Company Revenue Ranking in 2025
  2. 3.2 Global Primary Biliary Cirrhosis Drug Revenue by Company (2021-2026)
  3. 3.3 Global Primary Biliary Cirrhosis Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Primary Biliary Cirrhosis Drug Average Price by Company (2021-2026)
  5. 3.5 Global Primary Biliary Cirrhosis Drug Company Ranking (2024-2026)
  6. 3.6 Global Primary Biliary Cirrhosis Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Primary Biliary Cirrhosis Drug Company Product Type and Application
  8. 3.8 Global Primary Biliary Cirrhosis Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Primary Biliary Cirrhosis Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Primary Biliary Cirrhosis Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Primary Biliary Cirrhosis Drug Market by Type
  1. 4.1 Primary Biliary Cirrhosis Drug Type Introduction
  2. 4.1.1 Budesonide
  3. 4.1.2 NGM-282
  4. 4.1.3 MBX-8025
  5. 4.1.4 GSK-2330672
  6. 4.1.5 FFP-104
  7. 4.1.6 Others
  8. 4.2 Global Primary Biliary Cirrhosis Drug Sales Volume by Type
  9. 4.2.1 Global Primary Biliary Cirrhosis Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Primary Biliary Cirrhosis Drug Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Primary Biliary Cirrhosis Drug Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Primary Biliary Cirrhosis Drug Sales Value by Type
  13. 4.3.1 Global Primary Biliary Cirrhosis Drug Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Primary Biliary Cirrhosis Drug Sales Value by Type (2021-2032)
  15. 4.3.3 Global Primary Biliary Cirrhosis Drug Sales Value Share by Type (2021-2032)
5 Primary Biliary Cirrhosis Drug Market by Application
  1. 5.1 Primary Biliary Cirrhosis Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Primary Biliary Cirrhosis Drug Sales Volume by Application
  6. 5.2.1 Global Primary Biliary Cirrhosis Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Primary Biliary Cirrhosis Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Primary Biliary Cirrhosis Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Primary Biliary Cirrhosis Drug Sales Value by Application
  10. 5.3.1 Global Primary Biliary Cirrhosis Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Primary Biliary Cirrhosis Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Primary Biliary Cirrhosis Drug Sales Value Share by Application (2021-2032)
6 Primary Biliary Cirrhosis Drug Regional Sales and Value Analysis
  1. 6.1 Global Primary Biliary Cirrhosis Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Primary Biliary Cirrhosis Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Primary Biliary Cirrhosis Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Primary Biliary Cirrhosis Drug Sales by Region (2027-2032)
  5. 6.3 Global Primary Biliary Cirrhosis Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Primary Biliary Cirrhosis Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Primary Biliary Cirrhosis Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Primary Biliary Cirrhosis Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Primary Biliary Cirrhosis Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Primary Biliary Cirrhosis Drug Sales Value (2021-2032)
  12. 6.6.2 North America Primary Biliary Cirrhosis Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Primary Biliary Cirrhosis Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Primary Biliary Cirrhosis Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Primary Biliary Cirrhosis Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Primary Biliary Cirrhosis Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Primary Biliary Cirrhosis Drug Sales Value (2021-2032)
  21. 6.9.2 South America Primary Biliary Cirrhosis Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Primary Biliary Cirrhosis Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Primary Biliary Cirrhosis Drug Sales Value Share by Country, 2025 VS 2032
7 Primary Biliary Cirrhosis Drug Country-level Sales and Value Analysis
  1. 7.1 Global Primary Biliary Cirrhosis Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Primary Biliary Cirrhosis Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Primary Biliary Cirrhosis Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Primary Biliary Cirrhosis Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Primary Biliary Cirrhosis Drug Sales by Country (2027-2032)
  6. 7.4 Global Primary Biliary Cirrhosis Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Primary Biliary Cirrhosis Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Primary Biliary Cirrhosis Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AlbireoPharma
  2. 8.1.1 AlbireoPharma Company Information
  3. 8.1.2 AlbireoPharma Business Overview
  4. 8.1.3 AlbireoPharma Primary Biliary Cirrhosis Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 AlbireoPharma Primary Biliary Cirrhosis Drug Product Portfolio
  6. 8.1.5 AlbireoPharma Recent Developments
  7. 8.2 CymaBay Therapeutics, Inc.
  8. 8.2.1 CymaBay Therapeutics, Inc. Company Information
  9. 8.2.2 CymaBay Therapeutics, Inc. Business Overview
  10. 8.2.3 CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Product Portfolio
  12. 8.2.5 CymaBay Therapeutics, Inc. Recent Developments
  13. 8.3 Dr. Falk Pharma GmbH
  14. 8.3.1 Dr. Falk Pharma GmbH Company Information
  15. 8.3.2 Dr. Falk Pharma GmbH Business Overview
  16. 8.3.3 Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Product Portfolio
  18. 8.3.5 Dr. Falk Pharma GmbH Recent Developments
  19. 8.4 Enanta Pharmaceuticals, Inc.
  20. 8.4.1 Enanta Pharmaceuticals, Inc. Company Information
  21. 8.4.2 Enanta Pharmaceuticals, Inc. Business Overview
  22. 8.4.3 Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Portfolio
  24. 8.4.5 Enanta Pharmaceuticals, Inc. Recent Developments
  25. 8.5 Intercept Pharmaceuticals, Inc.
  26. 8.5.1 Intercept Pharmaceuticals, Inc. Company Information
  27. 8.5.2 Intercept Pharmaceuticals, Inc. Business Overview
  28. 8.5.3 Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Portfolio
  30. 8.5.5 Intercept Pharmaceuticals, Inc. Recent Developments
  31. 8.6 MediGene AG
  32. 8.6.1 MediGene AG Company Information
  33. 8.6.2 MediGene AG Business Overview
  34. 8.6.3 MediGene AG Primary Biliary Cirrhosis Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 MediGene AG Primary Biliary Cirrhosis Drug Product Portfolio
  36. 8.6.5 MediGene AG Recent Developments
  37. 8.7 NGM Biopharmaceuticals, Inc.
  38. 8.7.1 NGM Biopharmaceuticals, Inc. Company Information
  39. 8.7.2 NGM Biopharmaceuticals, Inc. Business Overview
  40. 8.7.3 NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Portfolio
  42. 8.7.5 NGM Biopharmaceuticals, Inc. Recent Developments
  43. 8.8 Virobay Inc.
  44. 8.8.1 Virobay Inc. Company Information
  45. 8.8.2 Virobay Inc. Business Overview
  46. 8.8.3 Virobay Inc. Primary Biliary Cirrhosis Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Virobay Inc. Primary Biliary Cirrhosis Drug Product Portfolio
  48. 8.8.5 Virobay Inc. Recent Developments
  49. 8.9 GlaxoSmithKline Plc
  50. 8.9.1 GlaxoSmithKline Plc Company Information
  51. 8.9.2 GlaxoSmithKline Plc Business Overview
  52. 8.9.3 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Product Portfolio
  54. 8.9.5 GlaxoSmithKline Plc Recent Developments
  55. 8.10 Johnson & Johnson
  56. 8.10.1 Johnson & Johnson Company Information
  57. 8.10.2 Johnson & Johnson Business Overview
  58. 8.10.3 Johnson & Johnson Primary Biliary Cirrhosis Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Johnson & Johnson Primary Biliary Cirrhosis Drug Product Portfolio
  60. 8.10.5 Johnson & Johnson Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Primary Biliary Cirrhosis Drug Value Chain Analysis
  2. 9.1.1 Primary Biliary Cirrhosis Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Primary Biliary Cirrhosis Drug Sales Mode & Process
  6. 9.2 Primary Biliary Cirrhosis Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Primary Biliary Cirrhosis Drug Distributors
  9. 9.2.3 Primary Biliary Cirrhosis Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst